van Rijswijk Rianne E, Bogdanovic Marko, Roy Joy, Yeung Kak Khee, Zeebregts Clark J, Geelkerken Robert H, Groot Jebbink Erik, Wolterink Jelmer M, Reijnen Michel M P J
Department of Vascular Surgery, Rijnstate, Arnhem, The Netherlands.
Multi-Modality Medical Imaging Group, Technical Medical Centre, University of Twente, Enschede, The Netherlands.
J Endovasc Ther. 2025 Jan 30:15266028251314359. doi: 10.1177/15266028251314359.
The goal of the study described in this protocol is to build a multimodal artificial intelligence (AI) model to predict abdominal aortic aneurysm (AAA) shrinkage 1 year after endovascular aneurysm repair (EVAR).
In this retrospective observational multicenter study, approximately 1000 patients will be enrolled from hospital records of 5 experienced vascular centers. Patients will be included if they underwent elective EVAR for infrarenal AAA with initial assisted technical success and had imaging available of the same modality preoperatively and at 1-year follow-up (CTA-CTA or US-US). Data collection will include baseline and vascular characteristics, medication use, procedural data, preoperative and postoperative imaging data, follow-up data, and complications.
The cohort will be stratified into 3 groups of AAA remodeling based on the maximum AAA diameter difference between the preoperative and 1-year postoperative moment. Patients with a diameter reduction of ≥5 mm will be assigned to the AAA shrinkage group, cases with an increase of ≥5 mm will be assigned to the AAA growth group, and patients with a diameter increase or reduction of <5 mm will be assigned to the stable AAA group. Furthermore, an additional fourth group will include all patients who underwent an AAA-related reintervention within the first year after EVAR, because both the complication and the reintervention might have influenced the state of AAA remodeling at 1 year. The preoperative and postoperative CTA scans will be used for anatomical AAA analysis and biomechanical assessment through semi-automatic segmentation and finite element analysis. All collected clinical, biomechanical, and imaging data will be used to create an AI prediction model for AAA shrinkage. Explainable AI techniques will be used to identify the most descriptive input features in the model. Predicting factors resulting from the AI model will be compared with conventional univariate and multivariate logistic regression analyses to find the best model for the prediction of AAA shrinkage. The study is registered at www.clinicaltrials.gov under the registration number NCT06250998.
This study aims to develop a robust and high-performance AI model for predicting AAA shrinkage one-year after EVAR, with great potential for optimizing both EVAR treatment and follow-up. The model can identify cases with an initially lower chance of early AAA shrinkage, in whom EVAR-treatment could be tailored by including additional preoperative coil embolization, active sac management and/or postoperative tranexamic acid therapy, which have shown to promote AAA shrinkage rate but are too complex and costly to perform in all patients. The model could aid in stratification of post-EVAR surveillance based on the patient's individual risk and possibly decrease follow-up for the 40-50% of patients who will experience AAA sac shrinkage. Overall, the AI prediction model is expected to improve patient survival and decrease the number of reinterventions after EVAR and associated healthcare costs.
本方案中描述的研究目标是构建一个多模态人工智能(AI)模型,以预测血管内动脉瘤修复术(EVAR)后1年腹主动脉瘤(AAA)的缩小情况。
在这项回顾性观察性多中心研究中,将从5个经验丰富的血管中心的医院记录中招募约1000名患者。如果患者因肾下腹主动脉瘤接受择期血管内动脉瘤修复术且初始辅助技术成功,并且术前和1年随访时有相同模态的影像学检查(CTA-CTA或US-US),则将其纳入研究。数据收集将包括基线和血管特征、药物使用、手术数据、术前和术后影像学数据、随访数据以及并发症。
根据术前和术后1年时腹主动脉瘤最大直径差异,将队列分为3组腹主动脉瘤重塑类型。直径缩小≥5mm的患者将被分配到腹主动脉瘤缩小组,直径增加≥5mm的病例将被分配到腹主动脉瘤生长组,直径增加或缩小<5mm的患者将被分配到稳定腹主动脉瘤组。此外,第四个额外的组将包括所有在血管内动脉瘤修复术后第一年内接受与腹主动脉瘤相关再次干预的患者,因为并发症和再次干预都可能影响1年时腹主动脉瘤重塑的状态。术前和术后的CTA扫描将用于通过半自动分割和有限元分析进行腹主动脉瘤解剖分析和生物力学评估。所有收集的临床、生物力学和影像学数据将用于创建腹主动脉瘤缩小的人工智能预测模型。将使用可解释人工智能技术来识别模型中最具描述性的输入特征。将人工智能模型得出的预测因素与传统单变量和多变量逻辑回归分析进行比较,以找到预测腹主动脉瘤缩小的最佳模型。该研究已在www.clinicaltrials.gov上注册,注册号为NCT06250998。
本研究旨在开发一个强大且高性能的人工智能模型,用于预测血管内动脉瘤修复术后1年腹主动脉瘤的缩小情况,在优化血管内动脉瘤修复术治疗和随访方面具有巨大潜力。该模型可以识别出早期腹主动脉瘤缩小可能性最初较低的病例,对于这些病例,可以通过包括额外的术前弹簧圈栓塞、积极的瘤腔管理和/或术后氨甲环酸治疗来调整血管内动脉瘤修复术治疗方案,这些措施已显示可提高腹主动脉瘤缩小率,但在所有患者中实施过于复杂且成本过高。该模型可根据患者个体风险辅助进行血管内动脉瘤修复术后监测分层,并可能减少40%-50%将会出现腹主动脉瘤瘤腔缩小的患者所需的随访。总体而言,人工智能预测模型有望提高患者生存率,减少血管内动脉瘤修复术后的再次干预次数及相关医疗费用。